

Reference	Study type	Number of patients (n male)	Anatomic location (%)	Hurley stage (%)	Intervention (comparator)	Dose	Comparator	Outcomes
O' Reilly et al 2005 (17)	Case report	1 (0)	Axillary	Not reported	Botulinum Toxin A	250 units per axilla	N/A	Complete resolution of symptoms for 10 months
Grimstad et al 2020 (26)	Randomised control trial	20 (3)	Axillary (25%) Axillary + groin (5%) Groin (40%) Groin + perineum (30%)	I (70%) II (25%) III (5%)	Botulinum toxin type B given at baseline and 3 months	Total dose per treatment area: 150 units per armpit, 200 units per groin and 600 units in the perineum	Saline placebo given at baseline, botulinum toxin type B given at 3 months	<p>Primary outcome measure</p> <p>Botox arm: DLQI score improved from median of 17 (10-21) to 8 (0-22) at 3 months (p< 0.05)</p> <p>Control arm: DLQI score improved from a median of 13.5 (2-21) to 11 (1-20) at 3 months (p > 0.05)</p> <p>Median DLQI score significantly decreased in cohort 2 from 3-6 months (11 vs 6.5, p< 0.01)</p> <p>Secondary outcome measures</p> <p>Perceived hidradenitis related impairment (VAS)</p> <p>Botox arm: Significant improvement in VAS score at three months (8 vs 3.5, p<0.01). Median VAS score of 7 at 6 months.</p> <p>Control arm: No significant difference in VAS score at 3 months (6 vs 5.5, p> 0.05)</p> <p>Number of nodules</p> <p>Botox arm: Significant reduction at 3 months (7.5 vs 3.5, p<0.01) and 6 months (7.5 vs 2, p<0.05)</p> <p>Control arm: No significant difference at 3 months (6 vs 2, p>0.05), significant reduction at 6 months (6 vs 1, p<0.05)</p> <p>Total number of lesions</p> <p>Botox arm: Significant reduction at 3 (9 vs 4, p<0.01) and 6 months (9 vs 2, p<0.01)</p> <p>Control arm: No significant difference at 3 months (6 vs 4.5, p>0.05), significant reduction at 6 months (6 vs 2, p<0.05)</p> <p>Self-reported pain in worse lesion (VAS)</p> <p>Botox arm Significant reduction at 6 months (8 vs 5, p<0.05)</p> <p>Control arm: No significant reduction at 6 months (7 vs 6.5, p>0.05)</p>

Feito-Rodriguez et al 2009 (27)	Case report	1 (0)	Groin	Not reported	Botulinum toxin-A	40 units	N/A	Complete remission for 6 months. Recurrence at 6 months.
Shi et al 2019 (28)	Case report	1 (0)	Axillary and inframammary	III	Botulinum toxin-A	400 units	N/A	Resolution of inflammation and healing of sinus tracts. 50% reduction in pain.
Campanati et al 2019 (29)	Case series	2 (1)	Axillary Groin	II II	Botulinum toxin-A	50 units each axilla 200 units total	N/A	'Real improvement' at 3 and 6 months. Patient 1 had repeat intervention at 10 months. No pain or difficulty in movement for both patients
Khoo et al 2014 (30)	Case report	1 (0)	Axillary	II	Botulinum toxin-A	25 units each axilla (four treatment courses over one year)	N/A	Disease remission sustained at 1 year follow up after fourth treatment

Supplementary Digital Content 2: Summary table of included studies